A5350: Effects of Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers

Study Location:

Topic:

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02706717?term=A5350&rank=1

Coordinator:

​Ilene Wiggins, RN 

Enrollment:

Closed

Trial Period:

Ongoing

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as persistent inflammation (irritation) and changes in the gut microbiome (microbial make-up). Researchers are studying the harmful effects of persistent inflammation and microbial changes in order to find ways to prevent these complications in HIV-infected patients. A5350 is a randomized, double-blind, two-arm pilot study of probiotic Visbiome Extra Strength therapy for 24 weeks. Visbiome Extra Strength is a probiotic with potential therapeutic effects on GI diseases. 

A substudy, A5352s, will be conducted in a subset of participants to collect colon biopsies via flexible sigmoidoscopy.   

Why is this study being done?
The purpose of the study is to learn more about the effects of Visbiome Extra Strength on GI damage in people who have HIV infection and to determine its safety and tolerability. We want to learn if treatment with Visbiome Extra Strength will decrease inflammation, improve gut health, and maintain these improvements after treatment.

The substudy will evaluate inflammation in the colon.  

Participants in the study must:

  • Have HIV infection
  • Be on stable HIV treatment for at least the last 24 weeks
  • Have undetectable (<50 copies) HIV viral load for at least 48 weeks
  • Have a CD4 count ≥200
  • Not have chronic hepatitis B or hepatitis C

​Ilene Wiggins, RN 
410-614-2766
iwiggin1@jhmi.edu 

Categories

Location
Topic

Clinical Trials

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More